Bacteria have evolved ways to evade the use of antimicrobials, leading to the rise of multidrug-resistant  bacteria. This is particularly true in the case of Gram-Negative  bacteria such as Acinetobacter baumannii, Klebsiella   pneumoniae, E.coli and Pseudomonas aeruginosa.                          


Given the high unmet medical need and the dwindling number   of  effective antibiotics, Bioharmony Therapeutics is  developing a pipeline of lysins for infections caused by   multidrug-resistant Gram-Negative bacteria.